Fingolimod (FTY720), a sphingosine-1-phosphate receptor (S1PR) modulator, is the first oral drug approved by the Food and Drug Administration (FDA) for the treatment of relapsing-remitting multiple sclerosis (RRMS) (Brinkmann et al., 2010). This evidence concerns the gene S1PR1 and relapsing-remitting multiple sclerosis.